Platform
MIR100: stopping the inflamation at the core
Miriditas is building a platform technology around MIR100, an innovative drug developed to interrupt inflammation at its source. MIR100 targets the initial immune response that leads to the activation of reactive oxygen species (ROS). MIR100 reduces ROS-related damage in retinal tissue and addresses the underlying pathogenesis of age-related macular degeneration (AMD).
Miriditas’s platform approach combines targeted molecular modulation with a focus on local ocular delivery and pharmacological precision. MIR100 is designed to modulate inflammatory signals without unnecessary systemic exposure, aiming to preserve retinal structure and function through early intervention in the inflammatory process.
Miriditas strategically positions its technology as scalable and modular: the platform supports the optimization of administration, formulation, and professional collaboration with clinical and industrial partners. The primary focus is on AMD, with the potential to extend this approach to other chronic, inflammation-driven conditions. For healthcare professionals and investors, Miriditas offers an evidence-based pathway to treatments that address the root cause of (retinal) inflammation.
